Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Kindly note that our content on Seeking Alpha and other platforms doesn't constitute financial advice ...

CHINA - 2024/09/06: In this photo illustration, the UnitedHealth Group logo is displayed on the ... [+] screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesUnitedHealth Group (NYSE: UNH) is scheduled to report its Q2 2024 results on Tuesday, October 15. We expect UnitedHealth to post revenue of $99 billion and earnings of $6.95 on a per-share and adjusted basis, slightly below the street expectations. The company will ...

Analysts on Wall Street project that UnitedHealth Group (UNH) will announce quarterly earnings of $7.02 per share in its forthcoming report, representing an increase of 7% year over year. Revenues are projected to reach $99.55 billion, increasing 7.8% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals ...

UnitedHealth Group Incorporated (UNH) is set to report third-quarter 2024 results on Oct. 15, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $7.02 per share on revenues of $99.6 billion. Growing premiums, commercial memberships and Optum business are expected to have supported its performance, partially affected by elevated expenses and lower Medicaid memberships.Stay up-to-date with all quarterly releases: See Zacks Earnings Cale ...

In the latest trading session, UnitedHealth Group (UNH) closed at $583.56, marking a -1.29% move from the previous day. This change lagged the S&P 500's 0.96% loss on the day. Elsewhere, the Dow lost 0.94%, while the tech-heavy Nasdaq lost 1.18%.Shares of the largest U.S. health insurer have depreciated by 0.95% over the course of the past month, outperforming the Medical sector's loss of 3.69% and lagging the S&P 500's gain of 4.3%.Analysts and investors alike will be keeping a close eye on the performance ...

The most recent trading session ended with UnitedHealth Group (UNH) standing at $584.68, reflecting a +0.49% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, added 0.38%. The the stock of largest U.S. health insurer has fallen by 1.41% in the past month, leading the Medical sector's loss of 2.49% and undershooting the S&P 500's gain of 2.06%. The investment community wi ...

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.The FTC's lawsuit, targeting these companies for allegedly inflating insulin prices, could have a major ripple effect across the healthcare industry—and that means stock volatility. So, which stock looks healthier?UnitedHealth Group: Big & Bold, But Under The Microscop ...

Core Allegations - The Federal Trade Commission (FTC) sued the three largest pharmacy benefit managers (PBMs) in the US, accusing them of steering diabetes patients towards higher-priced insulin to earn millions in rebates from pharmaceutical companies [1] - The PBMs allegedly excluded lower-cost insulin products from insurers' drug coverage lists, harming patients with coinsurance and deductibles who did not qualify for rebated prices [1] Market Dominance - The three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark, and Cigna's Express Scripts—administer 80% of all prescriptions in the US [2] Company Responses - CVS defended its efforts to make insulin more affordable, calling the FTC's allegations "simply wrong" and emphasizing its record of protecting patients from rising drug prices [2] - Cigna criticized the FTC for pursuing political points, arguing that forcing PBMs to include higher-cost drugs would increase overall drug prices [2] - Optum Rx dismissed the lawsuit as baseless, claiming it has reduced insulin costs for customers to an average of less than $18 per month [2] Stock Market Impact - CVS shares fell 1.6% in midday trading, while UnitedHealth and Cigna shares saw marginal declines [3] FTC's Perspective - The FTC described the PBMs as "medication gatekeepers" that have extracted millions from patients needing life-saving medications [4] - The agency criticized the role of major insulin manufacturers—Eli Lilly, Sanofi, and Novo Nordisk—in a "broken system" but did not sue them, reserving the right to do so later [4] Industry Dynamics - CVS Caremark argued that limiting PBMs' ability to negotiate drug prices would primarily benefit pharmaceutical companies [5] - The PBMs accused the FTC of bias, with Express Scripts suing the agency earlier in the week to withdraw a report claiming PBMs profit at the expense of smaller pharmacies [5] - The case will be heard by an FTC administrative law judge, with the process expected to move quickly and involve extensive evidence exchange [5]

UnitedHealth Group Incorporated (UNH) is currently viewed as expensive, with the stock trading at a 19.09X forward 12-month Price/Earnings (P/E), which is at a premium compared with the Zacks Medical – HMOs industry average of 16.67X.A premium valuation generally reflects the market’s strong confidence in the company's future prospects. UnitedHealth has a Value Score of B now. However, it is important to closely evaluate whether this elevated price is justified based on its growth prospects, fundamentals an ...

Core Viewpoint - UnitedHealth (UNH) was identified as a top investment idea for 2024 due to its strong operating plan and attractive valuation at 24x net income, but it has underperformed the S&P 500 by approximately 11% year-to-date [1][2]. Company Overview - UnitedHealth is a healthcare company focused on health insurance and healthcare facilitation, serving over 50 million members through its UnitedHealthcare division, which offers a wide range of health insurance plans [3]. - The company operates through various divisions, including Optum, which provides health services such as Pharmacy Benefit Management, Care Coordination, and Data Analytics [4]. Financial Performance - UNH has consistently beaten earnings expectations, with top-line sales growing at a mid-single-digit rate, although this growth has slowed year-over-year since the start of 2024 [5]. - Recent financial data indicates revenues for the three months ending in 2024 at $98.855 billion, with operating earnings of $7.875 billion [10]. Industry Challenges - The healthcare industry is facing headwinds, including a slowdown in Medicaid and Medicare expenditures, which have pressured margins across the sector [2][8]. - Key pressures include increasing utilization trends, misalignment between CMS rates and utilization, Medicaid redeterminations, rising competitive pressure, and regulatory scrutiny on Pharmacy Benefit Managers (PBMs) [8][9]. Cybersecurity Incident - UNH experienced a cyberattack affecting its Optum Insight segment, resulting in direct financial losses of approximately $22 million and significant reputational damage [7]. Future Outlook - Despite current challenges, there is optimism that headwinds will ease by 2025, with expectations for margin recovery as utilization ratios decrease and demand stabilizes post-COVID [12][13]. - The company is projected to rebound, with a price target of $700 per share over the next 12 months, driven by margin recovery and continued sales growth [19][21]. Valuation Metrics - UNH is currently trading at approximately 1.4x sales and 15x forward EV/EBITDA, which are considered attractive relative to its historical performance [15][21]. - The company’s P/E ratios indicate a premium valuation, but this is justified by its operational efficiency and market position [17].